Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma.

BACKGROUND: The functional consequence of airway obstruction in asthma can be regionally measured using inhaled gas MRI. Ventilation defects visualized by MRI persist post-bronchodilator in patients with severe asthma with uncontrolled sputum eosinophilia and may be due to eosinophil-driven airway pathology that is responsive to "anti-T2" therapy. RESEARCH QUESTION: Do anti-T2 therapies that clear eosinophils from the airway lumen decrease ventilation defects, measured by inhaled gas MRI, in adults with prednisone-dependent asthma? STUDY DESIGN AND METHODS: Inhaled hyperpolarized gas MRI was performed before and after bronchodilation in 10 prednisone-dependent patients with asthma with uncontrolled eosinophilic bronchitis (sputum eosinophils ≥3%) at baseline and 558 (100-995) days later when their eosinophilic bronchitis had been controlled (sputum eosinophils <3%) by additional anti-T2 therapy. The effect of anti-T2 therapy on ventilation defects, quantified as the MRI ventilation-defect-percent (VDP), was evaluated before and after bronchodilation for all patients and compared between patients dichotomized based on the median percentage of sputum eosinophils at baseline (15.8%). RESULTS: MRI VDP was improved pre- (ΔVDP+anti-T2: -3% ± 4%, P = .02) and post-bronchodilator (ΔVDP+anti-T2: -3% ± 4%; P = .04) after additional anti-T2 therapy that controlled eosinophilic bronchitis (n = 2 mepolizumab, n = 2 reslizumab, n = 3 benralizumab, n = 1 dupilumab, n = 2 increased daily prednisone). A greater post-bronchodilator ΔVDP+anti-T2 was observed in those patients with median or higher percentage of sputum eosinophils at baseline (≥15.8%; P = .01). In 7 of 10 patients with asthma, residual ventilation defects persisted despite bronchodilator and anti-T2 therapy. INTERPRETATION: Controlling sputum eosinophilia with anti-T2 therapies improves ventilation defects, measured by inhaled gas MRI, in adults with prednisone-dependent asthma.

Traqueobronquitis y neumonía asociada a ventilación mecánica por Chryseobacterium indologenes / Tracheo-bronchitis and pneumonia associated with mechanical ventilation by Chryseobacterium indologenes

El desarrollo de infecciones nosocomiales por gérmenes intrínsecamente resistentes a carbapenemes aumenta la mortalidad y provoca un aumento del gasto sanitario. El conocimiento y estudio de estas infecciones es importante a la hora de mejorar protocolos de actuación epidemiológicos y terapéuticos. Presentamos un estudio descriptivo, de 8 casos clínicos de pacientes con diagnóstico de traqueobronquitis y neumonía asociada a ventilación mecánica (NAVM) por Chryseobacterium indologenes (CBI), durante un periodo de 5 años. En esta serie de casos el aislamiento del CBI se produjo a los 11 días de media (rango 7-18) de permanecer los enfermos conectados a ventilación mecánica. La duración media de los pacientes en ventilación mecánica fue de 36 días (rango 10-140). La estancia media en UCI fue de 49 días (rango 14-180). Únicamente en un paciente no se aisló copatógeno concurrente a la traqueobronquitis o la NAVM por CBI. La mortalidad intrahospitalaria fue del 25%. La infección respiratoria nosocomial secundaria a CBI en pacientes con ventilación mecánica ha aumentado en los últimos años, por lo que se debería incluir en el diangóstico diferencial de la NAMV (AU)

The development of nosocomial infections by germs resistant to carbapenems inherently increases mortality, and causes an increase in health spending. The knowledge and study of these infections is important in improving epidemiological and therapeutic performance protocols. We present a descriptive study of eight patients diagnosed with tracheobronchitis (TAVM) and pneumonia (NAVM) associated with mechanical ventilation Chryseobacterium indologenes (CBI), over a period of five years. CBI isolation occurred at 11 days on average (rank 7-18) of remaining patients connected to mechanical ventilation. The average length of patients on mechanical ventilation was 36 days (range 10-140). The average ICU stay was 49 days (range 14-180). There was no death at 28 days, but the intra-hospital mortality was 2 cases (25%). Nosocomial respiratory infection secondary to CBI in mechanically ventilated patients has increased in recent years, so that should be included in the differential diagnostic of NAMV (AU)

[Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study]. / Skutecznosc i tolerancja syropu Bronchosol® w leczeniu ostrego zapalenia oskrzeli u doroslych. Porównanie z preparatami syntetycznymi zawierajacymi ambroksol--badanie obserwacyjne.

INTRODUCTION: Upper respiratory tract infections (URTI), including acute bronchitis, are the frequent health problems and the most common reason for acute cough in adults. Even though the infections are caused mainly by viruses, and their course is usually not complicated, febrifuges, i.a. mucokinetics, or antitussives are used in the treatment of URTI in order to improve the quality of life and safety of patients. THE AIM: To evaluate the efficacy and safety of Bronchosol® herbal syrup in comparison to ambroxol preparations in the treatment of acute bronchitis in adult patients. MATERIALS AND METHODS: The Bronchosol®/2013 study was a non-interventional, prospective, open-label, observational study. Data from adult patients treated with Bronchosol® syrup for acute bronchitis were collected and compared with data from patients treated for the same condition with ambroxol preparations. The severity of bronchitis symptoms was evaluated with the BSS (Bronchitis Severity Score) scale, and patients'quality of life wasassessed with the VAS (Visual Analogue Scale) scale. Between visits patients conducted self-observations and filled out observation diaries. Moreover, the data on adverse events were collected. RESULTS: In 87.68% of patients the infections were cured. Most of patients considered the studied drugs to be the agent decreasing the duration of infection and its intensity. The percentage of patients who declared that they had a less intense cough than during earlier infections was higher in the group of patients treated with Bronchosol® syrup in comparison to ambroxol treated patients (60.22% vs. 45.03%). 91.94% of patients treated with Bronchosol® considered this syrup to be very safe; in the ambroxol group such a declaration was made by 76.61% of patients. CONCLUSIONS: Bronchosol® syrup is an efficient, well-tolerated, and safe drug. Its efficacy in the treatment of acute bronchitis symptoms in adult patients is similar to the efficacy of ambroxol preparations.

[Intractable diarrhoea and severe weight loss by roflumilast]. / Diarrea intratable y pérdida ponderal acusada secundarias a roflumilast.

BACKGROUND AND OBJECTIVE: Roflumilast is a recently marketed drug, indicated for maintenance treatment of severe chronic obstructive pulmonary disease associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment. MATERIAL AND METHODS: The safety data of this drug have always been subjected to controversy and concerns. The Food and Drug Administration rejected the drug after the first evaluation, asking the company to clarify the adverse reactions during the investigation process, the European Medicines Agency approved the drug including a Risk Management Plan, designed to promote a safe use of the drug. RESULTS: During the first months after the marketing process, the Spanish Pharmacovigilance System has already been acquainted of several adverse events notifications; therefore, these patients may be closely monitored, mainly because of digestive and psychiatric disorders. CONCLUSIONS: Here we report the case of a female patient who showed a serious digestive clinical profile and a severe weight loss, more than 25% of her initial weight, when a treatment with roflumilast was started. The suspicion of a side effect as the cause of the reported clinical profile and its resolution required 3 hospital admissions.

[Diagnosing and treating cough]. / Udredning og behandling af hoste.

Cough is frequently a reason for seeing a doctor. Cough has a wide range of causes and the diagnosis can be difficult to make. Cough is often benign and self-limiting but can also be the first sign of malignancy. Especially chronic cough reduces the patients' quality of life. The purpose of this review was to present the most common reasons for cough, a rational method of investigation and a management protocol. Cough is a condition, which in most cases can be treated when using a systematic approach.

[Emergency treatment of epilepsy with Yamamoto New Scalp Acupuncture (YNSA) and body acupuncture ­ acupuncture in emergency medicine: a case report]. / Notfallbehandlung eines epileptischen Anfalls mit Yamamoto Neuer Schädelakupunktur (YNSA) und Körperakupunktur - Falldarstellung zur Akupunktur in der Notfallmedizin.

BACKGROUND: Worldwide, acupuncture is used in conflict areas and increasingly also as a supportive measure in emergency medicine. METHODS: In this case, the treatment of epilepsy, masseter cramp, unconsciousness and respiratory arrest by means of YNSA and body acupuncture with only 3 acupuncture needles is described. The 3 points used were YNSA basal ganglia point, Renzhong and Qiangu. RESULTS: After application of the needles, the epileptic fit stopped, the unconscious patient opened his mouth and started breathing spontaneously. CONCLUSION: In this case, acupuncture simplified the emergency procedure as a supportive treatment method and provided the patient with fast and safe relief.

Evaluación de la efectividad del renikan: extracto del pelargonium sidoides estandarizado EPs7630 en el tratmiento de las infecciones de las vías respiratorias superiores de etiología viral / Evaluation of the effectiveness of renikan: standardized extract of Pelargonium sidoides tratmiento EPs7630 in infections of the upper respiratory tract viral etiology

Las infecciones respiratorias, uno de los síndromes más frecuentes a nivel comunitario pueden ser de dos tipos: infecciones del tracto respiratorio superior o inferior. En su gran mayoría son inicadas por una infección viral transformando el terreno vulnerable a la sobre infección bacteriana. Hasta 2/3 de los pacientes son tratados desde el inicio de los síntomas con antibióticos, aunque este tratamiento no influye positivamente sobre el curso de la enfermedad. Renikan, fitofármaco extraído de la raíz del Pelargonium Sidoides, posee un triple mecanismo de acción: antiviral, antibacteriano y mucolítico, antiviral, porque activa los mecanismos de defensa antivirales orgánicos, antibacetriano, por su actividad bacteriostática directa e indirecta, y mucolítico, por sus propiedades secretomotoras y expectorantes. El objetivo fue comprobar la efectividad y tolerabilidad de Renikan en el tratamiento de las infecciones respiratorias. Diseño abierto y multicéntrico. Se seleccionaron niños de 6 a12 años y adultos de cualquier sexo o raza, con infecciones del tracto respiratorio superior. A los cuales se le suministró Renikan durante 7 días continuos, se evaluó: evolución de los síntomas, necesidad de uso de antibióticos y la escala de resultados integraticos IMOs. Ingreason un total 305 pacientes, 156 adultos y 149 niños distribuidos en tres grupos de estudio: Rinosinusitis, 97 pacientes, los cuales presentaron mejoría de sus síntomas en un 86% en los adultos y no utilizaron antibióticos en un 86%; los niños mejoraron en un 80%, y no usaron antibióticos en 91%. En el caso de las Amigdalitis hubo 108 pacientes con una mejoría sintomatológica en adultos del 92% y en los niños el 89%, no antibióticoterapia en el 86% de los adultos y 93% de los niños. El uso de Renikan en pacientes con infecciones del tracto respiratorio superior, demuestra ser seguro y efecivo tanto en adultos como en niños mayores de 6 años

Respiratory tract infections are the most common syndromes at community, there are two types: upper and lower respiratory tract infections. The vast majoritary are stared by a viral infection transforming the land vulnerable into a bacterial infection. The 2/3 o patients is treated from the onset of symptoms with antibiotics, although it is known that this treatment not positively influences the course of the disease. Renikan, herbal extrated fron the root of pelargonium sidoides has a threefold mechanism of action: antibiotic and mucolytic, antiviral, because it activates the natural antiviral mechanism of defense; antibacterial, due to its direct and indirect bacterostatic action and mucolytic, owing to its secretomotory and expectorant properties. To test the effectiveness and tolerability of renikan in the treatment of respiratory infections. Open desing, multicenter study. We selected children 6-12 years'age and adults of any sex orrance with upper respiratory tract infecctions. Theyreceived renikan for 7 consecutive days, changes in symptoms; necessity of antibiotic use and the integrative medicine outcome scale (IMOS) were evaluated. Of total of 305 patients, 156 adults and 149 children were divided into three groups: 97 rhinosinusitis patients, who showed symptoms improvement in 86% of adults and 91% of children, in 108 tonsillitis patients, an improvement of symptoms was found in 92% of adults and 89% of children, no antibiotic use were in 86% of adults and 93% of children, and, in a third group consistng of 100 patients with bronchitis, improvement was report in 98% od adults and in 73% of children, no antibiotics were used in 88% of adults and 96% of children. The use of concomitant therapy decreasedin 50% of cases and only 0.02% of patients had adverse events. The use of renikan use in patients with upper respiratory tract infections was shown to be safe and effective in both adults and children over 6 years of age

[Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. / Diagnóstico y tratamiento de las bronquiectasias. SEPAR.

Bronchiectasis is the end result of several different diseases that share principles of management. The clinical course usually involves chronic bronchial infection and inflammation, which are associated with progression. The cause of bronchiectasis should always be investigated, particularly when it can be treated. We recommend evaluating etiology, symptoms, bronchial colonization and infection, respiratory function, inflammation, structural damage, nutritional status, and quality of life in order to assess severity and to monitor clinical course. Care should be supervised by specialized units, at least in cases of chronic bronchial infection, recurrent exacerbations, or when there is a cause that is likely to respond to treatment. Improving symptoms and halting progression are the goals of management, which is based on treatment of the underlying cause and of acute or chronic infections and on the drainage of secretions. Complications that arise must also be treated. Antibiotic prescription is guided by how well infection is being controlled, and this is indicated by the color of sputum and a reduction in the number of exacerbations. We recommend inhaled antibiotics in cases of chronic bronchial infection that does not respond to oral antibiotics, when these cause side effects, or when the cause is Pseudomonas species or other bacteria resistant to oral antibiotics. Inhaled administration is also advisable to treat initial colonization by Pseudomonas species.

Evaluation of efficacy and tolerability of a fixed combination of dry extracts of thyme herb and primrose root in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled multicentre clinical trial.

STUDY OBJECTIVE: The objective of the study was to assess the efficacy and tolerability of a fixed combination of dry extracts of thyme herb and primrose root (thyme-primrose combination) and matched placebo in patients suffering from acute bronchitis with productive cough. METHODS: In a double-blind, placebo-controlled, multicentre Phase IV study, 361 outpatients with acute bronchitis and > or = 10 coughing fits during the day, onset of bronchial mucus production with impaired ability to cough up at a maximum of 2 days prior to recruitment, and a Bronchitis Severity Score (BSS) > or = 5 score points were randomly assigned to an 11-day treatment (1 tablet three times daily) with either thyme-primrose combination (Bronchipret TP FCT; N = 183) or placebo (N = 178). After the baseline examination (Visit 1 = Day 0), 2 control examinations were scheduled (Visit 2 = Day 4; Visit 3 = Day 10/end of treatment). The efficacy of the study treatment on acute bronchitis was evaluated by the patient's daily counting of coughing fits during the daytime (manual counter), assessment of acute bronchitis related symptoms and by the investigator's assessment of the most important symptoms of acute bronchitis using the BSS. Evaluation of tolerability was based upon adverse event (AE) monitoring, measurement of vital signs as well as the patient's and investigator's global judgement of tolerability at study end. Primary outcome was the change in frequency of coughing fits during daytime on days 7-9 according to patient's accurate daily recording with a manual counter and documentation in the diary. Treatment effects were analysed by analysis of variance (ANOVA) adjusted for centre effects. Due to significant deviation from the "preconditions" of the ANOVA, the Mann-Whitney-Wilcoxon test (stratified by centre) was carried out additionally. RESULTS: The mean reduction in coughing fits on days 7 to 9 relative to baseline (primary endpoint) was 67.1% under thyme-primrose combination compared to 51.3% under placebo (p < 0.0001). In the thyme-primrose combination group, a 50% reduction in coughing fits from baseline was reached about 2 days earlier compared to the placebo group. The symptoms of acute bronchitis (BSS) improved rapidly in both groups, but regression was faster and the responder rates compared to placebo were higher at Visit 2 (77.5% vs 60.1%; p = 0.0006) and Visit 3 (92.9% vs 75.8%; p < 0.0001) under the treatment of thyme-primrose combination. Treatment was well tolerated with no difference in the frequency or severity of AE between thyme-primrose combination and placebo groups. Severe or serious AE were not reported. CONCLUSION: Oral treatment of acute bronchitis with thyme-primrose combination for about 11 days was superior to placebo in terms of efficacy. The treatment was safe and well tolerated.

[Therapeutic effect of Xincang Decoction on chronic airway inflammation in children with bronchial asthma in remission stage].

OBJECTIVE: To observe the therapeutic effect of Xincang Decoction on chronic airway inflammation in children with asthma in clinical investigation. METHODS: Xincang Decoction was composed of Flos Magnoliae (Xinyi) and Fructus Xanthii (Cangoerzi), the traditional Chinese herbs for expelling wind. Sixty cases of children with bronchial asthma in remission stage were randomly divided into two groups. Thirty cases in the treatment group were treated with Xincang Decoction and the others in the control group were treated with ketotifen fumarate. The therapeutic effects of the two groups were compared, and the peripheral eosinophil (EOS) count, the levels of immunoglobulin E (IgE), interleukin 4 (IL-4) and interleukin 5 (IL-5), and the pulmonary functions were observed before and three months after the treatment. RESULTS: After three months treatment, the results showed that the total response rates of the treatment and the control group were 83.3% and 80.0%, respectively, without marked difference (P>0.05). The levels of EOS and IL-5 were obviously decreased after the treatment, and the levels of EOS and IL-5 of the patients in the treatment group were lower than those in the control group (P<0.05). Meanwhile the forced expiratory volume in one second (FEV(1)) was improved after the treatment, and the FEV(1) of the patients in the treatment group was higher than that of the patients in the control group (P<0.05). CONCLUSION: Xincang Decoction can decrease the levels of EOS and IL-5 and improve the pulmonary function in treating chronic airway inflammation in children with bronchial asthma in remission stage.

Effect of nasal triamcinolone acetonide on seasonal variations of bronchial hyperresponsiveness and bronchial inflammation in nonasthmatic children with seasonal allergic rhinitis.

BACKGROUND: Recent evidence suggests that patients with allergic rhinitis have lower airway inflammation and a higher prevalence of bronchial hyperresponsiveness (BHR) regardless of asthma. OBJECTIVE: To investigate markers of lower airway inflammation in nonasthmatic children with seasonal allergic rhinitis (SAR) before and during pollen season and the effect of nasal triamcinolone acetonide on seasonal variations in these parameters. METHODS: Thirty-two nonasthmatic children with SAR in response to grass and/or weed pollens were recruited and separated into 2 groups. Group 1 was treated with triamcinolone acetonide (220 microg once daily) for 6 weeks, and group 2 received no intranasal corticosteroid treatment. Bronchial responsiveness to methacholine [concentration that caused a decrease in forced expiratory volume in 1 second of 20% (PC20)], eosinophil counts in sputum and peripheral blood, and eosinophil cationic protein (ECP) levels in sputum and serum were measured before and during grass pollen season. RESULTS: Twenty-eight patients completed the study. During the pollen season, methacholine PC20 significantly decreased in both groups when compared with the corresponding preseasonal values (P = .01 and P = .003, respectively). The mean percentage of sputum eosinophils increased significantly during the pollen season compared with preseasonal values in group 1 and group 2 (12.7% +/- 2.1% vs 16.5% +/- 2.1%, P = .007, and 11.0% +/- 2.0% vs 20.2% +/- 1.4%, P = .003, respectively). Median [interquartile ranges (IQR)] sputum ECP levels were significantly higher during the pollen season when compared with the preseasonal values in group 1 and group 2 [7.5 microg/L (3.5-36.0 microg/L) vs 35.5 microg/L (13.0-71.7 microg/L), P = .04, and 18.0 microg/L (6.0-36.0 microg/L) vs 69.0 microg/L (39.0-195.0 microg/L), P = .003, respectively], as were the serum ECP levels [6.0 microg/L (2.0-13.0 microg/L) vs 19.0 microg/L (14.0-43.5 microg/L), P = .004, and 6.0 microg/L (3.0-7.0 microg/L) vs 18.0 microg/L (6.0-36.0 microg/L), P = .001, respectively]. Although the mean number of eosinophils in blood increased during the pollen season in both groups, it was only significant in group 2 (70.0 +/- 20.0 vs 161.6 +/- 29.0, P = .02). CONCLUSIONS: Although prophylactic nasal corticosteroid treatment provides significant reduction of nasal symptoms and rescue antihistamine use, there is no significant prevention in the seasonal increase of bronchial inflammation and methacholine BHR.

Treatment of cough and dyspnea due to acute bronchitis by plaster for cough and dyspnea--a report of 735 cases.

In the light of the theory of treating the internal disease externally, an externally used plaster for treating cough and dyspnea due to acute bronchitis (Ke Chuan Yi Tie Kang [symbol: see text]-[symbol: see text]) was successfully applied to 735 cases of acute bronchitis (the treatment group), with the other 423 cases treated with routine western drugs as controls. The results showed that the cure rate in the treatment group was significantly higher than that in the control group (P < 0.01); and that in the treatment group, the cure rate for the wind-cold type of acute bronchitis was significantly higher than that for the wind-heat type of acute bronchitis (P < 0.01).

[Biorhythm approach to the physiobalneotherapy of patients with chronic bronchitis and concomitant osteoarthrosis]. / Bioritmologicheskie podkhody k fiziobal'neolecheniiu bol'nykh khronicheskim bronkhitom s soputstvuiushchim osteoartrozom.

24-h rhythm of peak expiration rate and articular pain syndrome were studied in 92 patients with chronic bronchitis (CB) and osteoarthrosis. The findings were processed using cosinor program. 24 patients received mud applications on the joints and SHF-therapy (460 mH) on the joints and roots of the lung basing on the results of the biorhythmological studies. 18 patients served control. Advantages of the biorhythmological approach to the treatment are demonstrated.

Influencia del entorno ambiental y tipo de régimen dietético en la incidencia, duración e intensidad de los procesos infecciosos del lactante / The role of environmental factors and type of dietary regimen on morbidity in young infants

Objetivo. Estudiar las enfermedades infecciosas y su relación con el entorno ambiental en lactantes, desde su nacimiento hasta los 4 meses de edad. Material y Métodos. Han intervenido más de 600 pediatras. Se incluyó a niños de hasta 20 días que fueron reevaluados cuando tenían 4 meses, para estudiar las complicaciones infecciosas aparecidas. Análisis estadístico mediante regresión logística. Resultados. Se incluyeron 3.428 niños a término. Las infecciones oftálmicas fueron las más frecuentes (5,5 por ciento). Las bronquitis y neumonías las más graves (61 por ciento moderadas-graves) y de mayor duración (6,5 ñ 3 días). La polución, entorno fumador y convivencia con hermanos constituyen factores de riesgo. A los 4 meses, la administración de una fórmula sin nucleótidos se añadió a los factores de riesgo previos. Conclusiones. El entorno ambiental es importante en la incidencia de enfermedades infecciosas en el lactante. El riesgo aumenta por: asistencia a guarderías, polución y ambiente fumador. La alimentación con leche materna y una fórmula con nucleótidos son favorables para el desarrollo inmunológico de los lactantes. (AU)

Chlamydia / Chlamydia

Chlamydia pneumoniae ha sido identificado como una importante causa de enfermedades respiratorias en humanos. Este patógeno es transmitido persona a persona por transmisión aérea mediante secrecciones respiratorias. La infección es rara en niños menores de dos años, incrementándose la incidencia en edades escolares. Se estima que aproximadamente el 40 por ciento-60 por ciento de los adultos tienen anticuerpos contra C. pneumoniae. El diagnóstico se basa en la serología, normalmente microinmunofluorescencia (MIF), pero últimamente han aparecido nuevos métodos nuevos como PCR y cultivos mejorados. En niños, C. pneumoniae puede causar una variedad de enfermedades respiratorias como bronquitis, neumonía, sinusitis y faringitis. En los últimos años, se ha relacionado C. pneumoniae con una larga lista de enfermedades, incluyendo las enfermedades cardiovasculares. La hipótesis de que la infección en edades tempranas pueda dar lugar al desarrollo de arteriosclerosis en adultos está siendo evaluada actualmente. Si se confirma, la asociación reportada entre C. pneumoniae y arteriosclerosis podría llevar a el tratamiento de algunas enfermedades cardiovasculares con antibióticos como los macrólidos o las tetraciclinas, que son comúnmente activos contra la infección por C. pneumoniae (AU)

[Effect of diet enriched with marine omega-3 polyunsaturated fatty acids on microcirculation system in patients with cardiorespiratory pathology]. / Vliianie diety, obogashchennoi morskimi polinenasyshchennymi kislotami omega-3 na sostoianie mikrotsirkuliatornogo rusla u bol'nykh kardiorespiratornoi patologiei.

387 patients with cardiorespiratory pathology being under the influence of antiatherosclerotic diet were observed to have the positive dynamic of clinical picture of diseases, indices of microcirculatory channel and lipid spectrum of blood. Diet enrichment with polyunsaturated fatty acids omega-3 of sea origin favors the strengthening of corrected influence on lipid metabolism and microcirculatory state improving the miocard metabolism.

Consenso Latinoamericano sobre infecciones en bronquitis crónica / Latin American consensus on infections in chronic bronchitis

Dos tercios de las exacerbaciones agudas de la bronquitis crónica (EABC) se asocian con infección bacteriana y se caracterizan por recrudecimiento súbito de la tos, disnea y aumento en el volumen y el aspecto purulento del esputo. Las infecciones bacterianas crónicas o recurrentes, inician y perpetúan un círculo vicioso de daño a las vías aéreas, que se produce mediante la estimulación persistente de la cascada inflamatoria por los productos bacterianos. De los microorganismos causales, el más común es H. influenzae. Otros patógenos frecuentes incluyen M. catarrhalis, la mayoría resistentes a aminopenicilinas y S. Pneumoniae, el cual ha incrementado recientemente a su resistencia a penicilinas y macrólidos a nivel orbital. Si bien algunos estudios recientes han demostrado de manera clara el beneficio del tratamiento antibiótico de los EABC, existen ciertas dudas relacionadas con la manera de clasificar la enfermedad y con los criterios utilizados para la inclusión y exclusión de los pacientes, que permitan esclarecer de manera definitiva el beneficio del antimicrobiano en cada uno de los grupos en los que se ha clasificado su severidad. Con el fin de lograr un consenso sobre algunas de estas variables y establecer lineamientos racionales que permitan abordar el tratamiento de estos pacientes, se reunieron recientemente (noviembre del 96 y marzo del 97) un grupo de destacados expertos latinoamericanos en infectología y neumología. El consenso identificó una serie de factores de riesgo que permitieron diseñar una clasificación de EABC que establece cuatro grados de severidad; estos a su vez están relacionados con un grupo específico de microorganismos que varían con las circunstancias y desde luego en la sensibilidad a los antibióticos. Asimismo el grupo de expertos estableció que la resistencia de los gérmenes que comúnmente afectan a estos enfermos (H. influenzae, S. pneumoniae y M. catarrhalis) requieren de antimicrobianos que sean activos contra más del 90 por ciento de las cepas causantes. Como lineamientos prácticos terapéuticos, se sugirió que la traqueobronquitis aguda (clase I) no requiere en general de antibióticos; que la amoxicilina permanece como el tratamiento de elección para las exacerbaciones leves (clase II), mientras que para la bronquitis crónica complicada (clase III), algunas fluoroquinolonas (p.ej.: ciprofloxacina), los nuevos macrólidos, combinaciones con inhibidores de betalactamasa o cefalosporina orales de 3º generación...